Seven high-profile studies ranging from TAVR to lipid-lowering
ACC.16 is just around the corner, and Cleveland Clinic physicians are excited to be presenting or closely affiliated with seven late-breaking clinical trials or featured clinical research reports at the meeting.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
These potentially practice-changing studies are outlined below, along with where they fit in the program at ACC.16, the American College of Cardiology’s 65th Annual Scientific Session. Be sure to make room for these presentations in your itinerary for Chicago, and look for reports and commentary on these trials from Cleveland Clinic’s Consult QD blog soon after they are presented.
Session 401 — Late-Breaking Clinical Trials
Saturday, April 2, 8-10 a.m.
Transcatheter aortic valve replacement compared with surgery in intermediate-risk patients with aortic stenosis: Final results from the randomized Placement of Aortic Transcather Valves 2 (PARTNER 2) study.
Lead Cleveland Clinic investigators: Lars Svensson, MD, PhD, and Samir Kapadia, MD
Session 404 — Late-Breaking Clinical Trials
Sunday, April 3, 8-9:15 a.m.
Impact of the cholesteryl ester transfer protein inhibitor evacetrapib on cardiovascular events: Results of the ACCELERATE trial.
Presenter and Cleveland Clinic co-principal investigator: Stephen Nicholls, MBBS, PhD (A. Michael Lincoff, MD, is the other co-principal investigator)
Session 404 — Late-Breaking Clinical Trials
Sunday, April 3, 8-9:15 a.m.
Comparison of PCSK9 inhibitor evolocumab versus ezetimibe in statin-intolerant patients: The Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) trial.
Presenter and lead Cleveland Clinic investigator: Steven Nissen, MD
Session 405 — Late-Breaking Clinical Trials
Sunday, April 3, 10:45-noon
Sapien 3 transcatheter aortic valve replacement versus surgery in intermediate-risk patients with severe aortic stenosis: A propensity-matched comparison of one-year outcomes.
Lead Cleveland Clinic investigators: Lars Svensson, MD, PhD, and Samir Kapadia, MD
Session 410 — Late-Breaking Clinical Trials
Monday, April 4, 8-9:15 a.m.
Rate vs. Rhythm: A randomized trial of rate control versus rhythm control for atrial fibrillation after cardiac surgery.
Presenter and lead Cleveland Clinic investigator: A. Marc Gillinov, MD
Session 412 — Late-Breaking Clinical Trials
Monday, April 4, 10:45-noon
INOVATE-HF: The effect of vagal nerve stimulation in heart failure: Primary results of the INcrease Of VAgal TonE in chronic Heart Failure (INOVATE-HF) trial.
Lead Cleveland Clinic investigator: Randall Starling, MD, MPH
Session 416 — Featured Clinical Research Session II
Monday, April 4, 2-3:30 p.m.
Bariatric surgery vs. intensive medical therapy for long-term glycemic control and complications of diabetes: Final 5-year STAMPEDE trial results.
Presenter and lead Cleveland Clinic investigator: Philip Schauer, MD
Further acute testing not needed if ECG and high-sensitivity troponin are negative
Scott Cameron, MD, PhD, also brings wide-ranging research interests to bear
Pioneering U.K. vascular surgeon joins Cleveland Clinic
AHA statement is first comprehensive document on perioperative stroke reduction
Recognition reflects prioritization of long-term patient outcomes
Recommendations help distinguish exercise-induced remodeling from pathology
JACC review highlights factors unique to women, ways to tailor management
Pushing the envelope in ablation of atrial fibrillation, ventricular tachycardia